Omega-3 Augmentation of Sertraline in Treatment of Depression in Patients With Coronary Heart Disease

Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: A randomized, double-blind placebo-controlled study

“…Treatment was not specified for 1 person in the E-EPA arm (loss to follow-up) and for 1 person in the placebo arm. PUFAs augmentation of sertraline was superior to sertraline plus placebo for the treatment of depression (Carney et al, 2009). However, there are clear differences between our study and the other studies in sample characteristics (diabetes patients vs. other patient groups) and the ω-3 PUFAs provided.…”

“…A recent meta-analysis showed that ω-3 PUFAs were efficacious as antidepressant therapy (Appleton et al, 2010) , although heterogeneity in study design was noted. However, a recent study did not observe an effect of ω-3 PUFAs on mood in depressed patients with a coronary heart disease (Carney et al, 2009). Furthermore, there is some evidence that EPA may be particularly effective as add-on treatment in patients with major depression using antidepressant medication (Pouwer et al, 2005;Sarris et al, 2009).…”

Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease

“…[210][211][212] Recent studies have drawn into question the role of omega-3 treatment for secondary prevention of CVD in the general population, 213 as well as for adjunctive treatment of depression among adults with CVD. 214 However, given the above findings, future studies examining the impact of omega-3 treatment on CVD-relevant outcomes (eg, endothelial function, inflammation) and mood symptoms among youth with MDD and BD are warranted.…”

Diagnosis and Treatment of Depression and its Outcomes in Patients with Coronary Heart Disease (CHD): A Literature Review

“…Some studies have used a random sample selection method [16], while others have another sampling method to develop a representative sample of the population [2,3]. Nevertheless, some studies have chosen to focus on either people with depression or patients with CHD [11], as a specific sample for their research [16].…”